METHYLPREDNISOLONE

Post-LOE

methylprednisolone sodium succinate

Bristol Myers Squibb

ANDAINJECTIONINJECTABLE

Approved

Feb 1980

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

METHYLPREDNISOLONE (methylprednisolone sodium succinate) by Bristol Myers Squibb is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, temporal arteritis, polymyositis and 15 more indications. First approved in 1980.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…

Indications (18)

dermatomyositis

Worked on METHYLPREDNISOLONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT07353749Phase 4Not Yet Recruiting

Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms

Started Jan 2026

864 enrolled

Unruptured Intracranial AneurysmsCerebrovascular EventHemorrhagic Stroke+2 more

NCT07101445Phase 4Recruiting

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Started Sep 2025

94 enrolled

Multiple Myeloma

NCT06623370Phase 4Completed

The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group

Started Oct 2024

NCT05532072Phase 1Unknown

Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.

Started Sep 2022

140 enrolled

Graves Ophthalmopathy

NCT04016025Phase 4Completed

A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers

Started Dec 2020

80 enrolled

Adherence, PatientChronic Eczema